Cardiac cell-repair therapy: Clinical issues

Bernard J. Gersh, Robert D. Simari

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


The possibility that cardiac cell-repair therapy might become a clinical reality is a challenge worthy of the current state of technological and scientific expertise at the start of the 21st century. The success of preclinical and early clinical studies is a strong inducement to move ahead with larger clinical trials, but caution is warranted given our lack of understanding of the potential mechanisms by which cell-repair therapy exerts a benefit on ventricular function, perfusion, and infarct size, irrespective of the type of cell, method, site, and disease entity. There are multiple clinical, mechanistic, and safety questions requiring answers, and these will be forthcoming only if the design of clinical trials is carefully tailored to answer specific questions. These questions, in turn, will require the use of different and multiple end points, depending on the specific issue and study. Accordingly, this review addresses the limitations of current clinical studies, the design of future trials, and the concept of a hierarchical series of end points that might provide answers to a host of different questions. Clinical and basic scientists need to approach the next generation of trials in partnership.

Original languageEnglish (US)
Pages (from-to)S105-S109
JournalNature Clinical Practice Cardiovascular Medicine
Issue numberSUPPL. 1
StatePublished - Mar 2006


  • Cardiac cell-repair
  • Clinical trials
  • Congestive heart failure
  • Myocardial infarction
  • Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Cardiac cell-repair therapy: Clinical issues'. Together they form a unique fingerprint.

Cite this